CytomX Therapeutics, Inc. $CTMX Shares Sold by Exome Asset Management LLC

Exome Asset Management LLC cut its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 30.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 521,468 shares of the biotechnology company’s stock after selling 223,837 shares during the quarter. Exome Asset Management LLC owned about 0.31% of CytomX Therapeutics worth $2,451,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in CTMX. Wells Fargo & Company MN increased its stake in shares of CytomX Therapeutics by 83.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of CytomX Therapeutics in the fourth quarter worth approximately $35,000. Lido Advisors LLC purchased a new stake in CytomX Therapeutics in the first quarter valued at approximately $49,000. May Hill Capital LLC purchased a new stake in CytomX Therapeutics in the fourth quarter valued at approximately $46,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in CytomX Therapeutics during the first quarter worth approximately $52,000. 67.77% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have weighed in on CTMX shares. Wall Street Zen raised shares of CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Zacks Research raised shares of CytomX Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Weiss Ratings restated a “sell (d)” rating on shares of CytomX Therapeutics in a report on Tuesday, June 16th. Wolfe Research began coverage on CytomX Therapeutics in a research report on Tuesday, May 19th. They issued an “outperform” rating and a $6.00 target price on the stock. Finally, HC Wainwright reduced their target price on CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, CytomX Therapeutics has an average rating of “Buy” and an average target price of $12.10.

CytomX Therapeutics Stock Performance

NASDAQ CTMX opened at $3.25 on Tuesday. The firm has a market capitalization of $553.12 million, a price-to-earnings ratio of -7.93 and a beta of 2.08. CytomX Therapeutics, Inc. has a one year low of $1.72 and a one year high of $8.21. The company’s 50 day moving average price is $3.43 and its 200 day moving average price is $4.34.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. CytomX Therapeutics had a negative net margin of 166.40% and a negative return on equity of 36.61%. The company had revenue of $10.26 million during the quarter, compared to the consensus estimate of $4.68 million. Sell-side analysts forecast that CytomX Therapeutics, Inc. will post -0.45 EPS for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.